X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VERU-024 (enobosarm) is a novel oral daily selective androgen receptor modulator.
Lead Product(s): Enobosarm,GLP-1 receptor agonist
Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
VERU-024 (enobosarm) is a novel selective androgen receptor modulator which is beig evaluated in preclinical studies to prevent muscle loss while augmenting fat loss in combination with GLP-1 drugs for weight loss.
Lead Product(s): Enobosarm,Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Veru intends to use the proceeds to fund its clinical stage drug development, including a Phase 2b trial to evaluate VERU-024 (enobosarm), an oral selective androgen receptor modulator, for the treatment to augment fat loss and to prevent muscle loss in sarcopenic obese.
Lead Product(s): Enobosarm,Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 14, 2023
Details:
Veru intends to use the proceeds to fund its clinical stage drug development, including a Phase 2b trial to evaluate VERU-024 (enobosarm), an oral selective androgen receptor modulator, for the treatment to augment fat loss and to prevent muscle loss in sarcopenic obese.
Lead Product(s): Enobosarm,Undisclosed
Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2023
Details:
VERU-024 (enobosarm), a selective androgen receptor modulator, into a Phase 2b clinical trial in combination with semaglutide to evaluate the efficacy and the safety of enobosarm to further increase fat loss.
Lead Product(s): Enobosarm,Abemaciclib,Tirzepatide
Therapeutic Area: Nutrition and Weight Loss Product Name: VERU-024
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
VERU-111 (sabizabulin) is an oral, first-in-class small molecule that targets, binds to, and crosslinks the alpha and beta tubulin subunits of microtubules and intermediate filaments of cells resulting in disruption of inflammatory cell activities.
Lead Product(s): Sabizabulin
Therapeutic Area: Infections and Infectious Diseases Product Name: VERU-111
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
VERU-024 (enobosarm), a first-in-class, oral, non-steroidal, selective androgen receptor agonist, which is investigating for the treatment of metastatic setting of AR+ER+HER2- breast cancer.
Lead Product(s): Enobosarm,Abemaciclib
Therapeutic Area: Oncology Product Name: VERU-024
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
VERU-111 (sabizabulin) is an oral, first-in-class small molecule that targets, binds to, and crosslinks the alpha and beta tubulin subunits of microtubules and intermediate filaments of cells resulting in disruption of inflammatory cell activities.
Lead Product(s): Sabizabulin
Therapeutic Area: Infections and Infectious Diseases Product Name: VERU-111
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
The acquisition transforms the Company into a broader pharmaceutical company spanning multiple sectors by including ENTADFI (finasteride), an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a PDE5 inhibitor.
Lead Product(s): Finasteride,Tadalafil
Therapeutic Area: Urology Product Name: Entadfi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Water Vaccines
Deal Size: $100.0 million Upfront Cash: $20.0 million
Deal Type: Agreement April 20, 2023
Details:
VERU-111 (sabizabulin) prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells, reported in a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus.
Lead Product(s): Sabizabulin
Therapeutic Area: Infections and Infectious Diseases Product Name: VERU-111
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
